Prenatal Iron and Malaria Study (PIMAL)
Primary Purpose
Malaria
Status
Completed
Phase
Phase 4
Locations
Kenya
Study Type
Interventional
Intervention
iron
Sponsored by
About this trial
This is an interventional prevention trial for Malaria focused on measuring Iron, Plasmodium, Malaria, Pregnancy, Kenya
Eligibility Criteria
Inclusion Criteria:
- Women aged 15-45 years resident in the predefined study area
- Pregnant, with gestational age <23 weeks
Exclusion Criteria:
- Failure to provide a blood sample
- Initial haemoglobin concentration <90 g/L
- Reported medical history suggestive of sickle cell anaemia, epilepsy, diabetes
- Obstetric history suggestive of eclampsia or pre-eclampsia
- Obvious mental retardation or metabolic disorder;
- No written consent
- Carrying multiples
- Woman planning to leave the homestead or to be absent for prolonged periods in the course of the pregnancy or within a 1-month period thereafter
- Woman planning to deliver outside the research clinic.
Sites / Locations
- University of Nairobi
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Supplemental iron
Placebo
Arm Description
Outcomes
Primary Outcome Measures
Maternal Plasmodium infection
Assessed by LDH- and HRP2-based dipstick test and PCR
Secondary Outcome Measures
Serum non-transferrin bound iron concentration
Neonatal iron stores
Assessed by plasma ferritin concentration, restricted to infants without inflammation
Maternal iron status
To be assessed by haemoglobin concentrations, prevalence of iron deficiency anaemia (plasma ferritin concentration <12 µg/L) and iron stores (ratio of ferritin:transferrin receptor concentrations); indicators based on ferritin and/or transferrin receptor will be restricted to those without inflammation.
Maternal intestinal pathogens
Full Information
NCT ID
NCT01308112
First Posted
March 2, 2011
Last Updated
May 28, 2013
Sponsor
London School of Hygiene and Tropical Medicine
Collaborators
University of Nairobi, Wageningen University
1. Study Identification
Unique Protocol Identification Number
NCT01308112
Brief Title
Prenatal Iron and Malaria Study
Acronym
PIMAL
Official Title
A Randomised Trial to Assess the Safety and Efficacy or Iron Supplementation in Kenyan Pregnant Women
Study Type
Interventional
2. Study Status
Record Verification Date
May 2013
Overall Recruitment Status
Completed
Study Start Date
October 2011 (undefined)
Primary Completion Date
April 2013 (Actual)
Study Completion Date
May 2013 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
London School of Hygiene and Tropical Medicine
Collaborators
University of Nairobi, Wageningen University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to compare the presence of Plasmodium infection in parturient women who antenatally received a combination of iron-fortified foods with iron supplements versus iron-fortified foods only.
Detailed Description
As per recommendations by the World Health Organization (WHO), iron supplementation in children should be restricted in malaria-endemic areas because of concerns that it can lead to an increased burden of malaria. Universal iron supplementation continues to be recommended, however, for women during pregnancy and 3 months postpartum. Observational studies have shown that iron deficiency in parturient women is associated with a marked reduction in the prevalence and density of malarial parasites in the placenta. Plasmodium infections in pregnant women have devastating effects on the foetus and neonate, causing low birth weight, intrauterine growth retardation, preterm delivery, spontaneous abortion, stillbirth and neonatal mortality. Based on our previous work, the Kenyan government is currently drafting legislation for mandatory iron fortification of industrially milled flour. Implementation of the new fortification policy means that pregnant women will receive iron through a combination of fortified foods and supplementation. The investigators are concerned about the safety of the high iron intake resulting from such a policy.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Malaria
Keywords
Iron, Plasmodium, Malaria, Pregnancy, Kenya
7. Study Design
Primary Purpose
Prevention
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
470 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Supplemental iron
Arm Type
Experimental
Arm Title
Placebo
Arm Type
Placebo Comparator
Intervention Type
Dietary Supplement
Intervention Name(s)
iron
Intervention Description
Daily supplementation with iron (60 mg) as ferrous sulphate
Primary Outcome Measure Information:
Title
Maternal Plasmodium infection
Description
Assessed by LDH- and HRP2-based dipstick test and PCR
Time Frame
Parturition
Secondary Outcome Measure Information:
Title
Serum non-transferrin bound iron concentration
Time Frame
3 h after ingestion of first supplement with either iron or placebo
Title
Neonatal iron stores
Description
Assessed by plasma ferritin concentration, restricted to infants without inflammation
Time Frame
At 1 month of age
Title
Maternal iron status
Description
To be assessed by haemoglobin concentrations, prevalence of iron deficiency anaemia (plasma ferritin concentration <12 µg/L) and iron stores (ratio of ferritin:transferrin receptor concentrations); indicators based on ferritin and/or transferrin receptor will be restricted to those without inflammation.
Time Frame
At 1 month after delivery
Title
Maternal intestinal pathogens
Time Frame
At 1 month after delivery
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
15 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Women aged 15-45 years resident in the predefined study area
Pregnant, with gestational age <23 weeks
Exclusion Criteria:
Failure to provide a blood sample
Initial haemoglobin concentration <90 g/L
Reported medical history suggestive of sickle cell anaemia, epilepsy, diabetes
Obstetric history suggestive of eclampsia or pre-eclampsia
Obvious mental retardation or metabolic disorder;
No written consent
Carrying multiples
Woman planning to leave the homestead or to be absent for prolonged periods in the course of the pregnancy or within a 1-month period thereafter
Woman planning to deliver outside the research clinic.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Hans Verhoef, PhD
Organizational Affiliation
London School of Hygiene and Tropical Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Nairobi
City
Nairobi
Country
Kenya
12. IPD Sharing Statement
Citations:
PubMed Identifier
26348751
Citation
Mwangi MN, Roth JM, Smit MR, Trijsburg L, Mwangi AM, Demir AY, Wielders JP, Mens PF, Verweij JJ, Cox SE, Prentice AM, Brouwer ID, Savelkoul HF, Andang'o PE, Verhoef H. Effect of Daily Antenatal Iron Supplementation on Plasmodium Infection in Kenyan Women: A Randomized Clinical Trial. JAMA. 2015 Sep 8;314(10):1009-20. doi: 10.1001/jama.2015.9496.
Results Reference
derived
PubMed Identifier
25428714
Citation
Mwangi MN, Maskey S, Andang o PE, Shinali NK, Roth JM, Trijsburg L, Mwangi AM, Zuilhof H, van Lagen B, Savelkoul HF, Demir AY, Verhoef H. Diagnostic utility of zinc protoporphyrin to detect iron deficiency in Kenyan pregnant women. BMC Med. 2014 Nov 26;12:229. doi: 10.1186/s12916-014-0229-8.
Results Reference
derived
Learn more about this trial
Prenatal Iron and Malaria Study
We'll reach out to this number within 24 hrs